GAITHERSBURG, Md., May 18, 2020 /PRNewswire/ -- MaxCyte, the
global clinical-stage cell-based therapies and life sciences
company, announces that clinical data from the first three cohorts
of the ongoing Phase I dose-escalation trial demonstrating safety
of MCY-M11 and feasibility of one-day manufacturing will be shared
at the American Society of Clinical Oncology's (ASCO) upcoming
annual meeting. The ASCO20 Virtual Scientific Program will be held
May 29-31, 2020.
The Poster Discussion presentation,
entitled Feasibility and preliminary safety
and efficacy of first-in-human intraperitoneal delivery of MCY-M11,
anti-human-mesothelin CAR mRNA transfected into peripheral blood
mononuclear cells, for ovarian cancer and malignant peritoneal
mesothelioma, will be available in the Developmental
Therapeutics: Immunotherapy session, which can be accessed on
demand beginning at 8 a.m. ET on Friday, May
29, 2020.
MCY-M11 is a wholly-owned, non-viral, mRNA-based cell therapy
candidate manufactured using un-manipulated peripheral blood
mononuclear cells. It is under development for the treatment
of ovarian cancer and peritoneal mesothelioma. The ongoing study so
far demonstrates both the safety and of MCY-M11 as well as the
feasibility of one-day manufacturing and intraperitoneal delivery
of our cell product.
"This is a presentation of the preliminary results of our
ongoing first-in-human study with the novel mRNA-based CARMA
platform designed to treat malignancies expressing mesothelin,"
said Christina M. Annunziata, MD, PhD, Investigator at
the Women's Malignancies Branch and Head of the Translational
Genomics Section at the National Cancer Institute Center for Cancer
Research. "We have so far demonstrated the feasibility to deliver
MCY-M11 CARMA cells intraperitoneally to treat patients, the
acceptable overall safety of using a transient CAR expression
approach and early evidence that supports moving forward with and
further building on this strategy."
As previously announced, dosing began in October 2019 in the third cohort in
MaxCyte's Phase I dose-escalation trial with MCY-M11 and there
have been no dose-limiting toxicities or related serious adverse
events observed in the three completed cohorts. A fourth
dosing cohort commenced in March 2020 as expected. Preliminary
clinical results for the trial are expected to be announced in H2
2020. Clinical development of MCY-M11 continues now under the
auspices of MaxCyte's subsidiary CARMA Cell Therapies™.
For more information about the ASCO20 Virtual Scientific Program
and a link to the abstract, please visit:
https://meetinglibrary.asco.org/record/185279/abstract.
About CARMA Cell Therapies
Through its wholly owned
subsidiary, CARMA Cell Therapies, MaxCyte is facilitating
advancement of novel mRNA-based cell therapies for cancer and other
diseases with serious unmet needs. MaxCyte has developed
CARMA, a novel and proprietary platform for the development of
non-viral, human messenger RNA (mRNA)-based, chimeric antigen
receptor (CAR) or T-cell receptor (TCR) redirected immune cell
therapies. CARMA [derived from CAR mRNA] utilizes
MaxCyte's Flow Electroporation® technology for highly efficient,
non-viral, delivery of one or more mRNA(s) into
un-manipulated peripheral blood mononuclear cells (PBMCs) or
isolated immune cells such as T- or NK-cells. CARMA offers the
potential for a safer cell therapy, as a result of transient
expression of receptor(s) and a non-viral delivery approach.
Together, CARMA and MaxCyte's EXPERT® family of instruments also
offer the potential for a significantly streamlined, scalable, and
cost-effective GMP manufacturing process without the complexity of
virus-based products. At the start of 2020, MaxCyte
established CARMA Cell Therapies as a wholly owned subsidiary to
facilitate independent investment and new partnerships to advance
the CARMA platform. MaxCyte has retained Locust Walk, a
global life science strategic advisory and transaction
firm. The Company expects CARMA to be self-funded by end of
2020. For more information,
visit https://www.maxcyte.com/carma-cell-therapies/.
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life
sciences company. As the inventors of the premier cell-engineering
enabling technology, the Company helps bring the promise of
next-generation cell and gene-editing therapies to life. The
Company's technology is currently being deployed by leading
drug developers worldwide, including all of the top ten global
biopharmaceutical companies. MaxCyte licenses have been
granted for more than 100 cell therapy programmes, with more than
70 licensed for clinical use, and the Company has now entered into
ten clinical/commercial license agreements with leading cell
therapy and gene editing developers. MaxCyte was founded in 1998
and is headquartered in Gaithersburg,
Maryland, US. For more information,
visit www.maxcyte.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/maxcyte-to-share-preliminary-phase-i-data-on-mcy-m11-at-asco-2020-annual-meeting-301060478.html
SOURCE MaxCyte, Inc.